1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. MAP3K
  4. MAP3K7/TAK1 Isoform

MAP3K7/TAK1

 

MAP3K7/TAK1 Related Products (7):

Cat. No. Product Name Effect Purity
  • HY-103490
    Takinib
    Inhibitor 99.31%
    Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC50=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (KD(app) of 0.46 μM).
  • HY-12686
    5Z-7-Oxozeaenol
    Inhibitor 99.60%
    5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of 8 nM and 52 nM, respectively.
  • HY-15434
    NG25
    Inhibitor 99.35%
    NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.
  • HY-132172
    TAK1-IN-2
    Inhibitor 98.22%
    TAK1-IN-2 is a potent and selective TAK1 inhibitor, with an IC50> of 2 nM.
  • HY-77251
    TAK1/MAP4K2 inhibitor 1
    Inhibitor 98.07%
    TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
  • HY-115743
    TAK1-IN-3
    Inhibitor 98.88%
    TAK1-IN-3 is a potent ATP-competitive TAK1 inhibitor.
  • HY-122642
    TAK1-IN-4
    Inhibitor 99.47%
    TAK1-IN-4 (Compound 14) is a TAK1 inhibitor.
Cat. No. Product Name / Synonyms Application Reactivity